These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
287 related articles for article (PubMed ID: 31878950)
1. The potassium channel KCa3.1 represents a valid pharmacological target for microgliosis-induced neuronal impairment in a mouse model of Parkinson's disease. Lu J; Dou F; Yu Z J Neuroinflammation; 2019 Dec; 16(1):273. PubMed ID: 31878950 [TBL] [Abstract][Full Text] [Related]
2. Ca Yu Z; Dou F; Wang Y; Hou L; Chen H J Neuroinflammation; 2018 Nov; 15(1):316. PubMed ID: 30442153 [TBL] [Abstract][Full Text] [Related]
3. Loss of collapsin response mediator protein 4 suppresses dopaminergic neuron death in an 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse model of Parkinson's disease. Tonouchi A; Nagai J; Togashi K; Goshima Y; Ohshima T J Neurochem; 2016 Jun; 137(5):795-805. PubMed ID: 26991935 [TBL] [Abstract][Full Text] [Related]
4. KCa3.1 deficiency attenuates neuroinflammation by regulating an astrocyte phenotype switch involving the PI3K/AKT/GSK3β pathway. Wei T; Wang Y; Xu W; Liu Y; Chen H; Yu Z Neurobiol Dis; 2019 Dec; 132():104588. PubMed ID: 31470105 [TBL] [Abstract][Full Text] [Related]
5. Macrophage antigen complex-1 mediates reactive microgliosis and progressive dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Hu X; Zhang D; Pang H; Caudle WM; Li Y; Gao H; Liu Y; Qian L; Wilson B; Di Monte DA; Ali SF; Zhang J; Block ML; Hong JS J Immunol; 2008 Nov; 181(10):7194-204. PubMed ID: 18981141 [TBL] [Abstract][Full Text] [Related]
6. The potassium channel KCa3.1 constitutes a pharmacological target for astrogliosis associated with ischemia stroke. Yi M; Wei T; Wang Y; Lu Q; Chen G; Gao X; Geller HM; Chen H; Yu Z J Neuroinflammation; 2017 Oct; 14(1):203. PubMed ID: 29037241 [TBL] [Abstract][Full Text] [Related]
7. TRPV4 contributes to ER stress and inflammation: implications for Parkinson's disease. Liu N; Bai L; Lu Z; Gu R; Zhao D; Yan F; Bai J J Neuroinflammation; 2022 Jan; 19(1):26. PubMed ID: 35093118 [TBL] [Abstract][Full Text] [Related]
9. Amentoflavone protects dopaminergic neurons in MPTP-induced Parkinson's disease model mice through PI3K/Akt and ERK signaling pathways. Cao Q; Qin L; Huang F; Wang X; Yang L; Shi H; Wu H; Zhang B; Chen Z; Wu X Toxicol Appl Pharmacol; 2017 Mar; 319():80-90. PubMed ID: 28185818 [TBL] [Abstract][Full Text] [Related]
10. Assessment of the Effects of MPTP and Paraquat on Dopaminergic Neurons and Microglia in the Substantia Nigra Pars Compacta of C57BL/6 Mice. Smeyne RJ; Breckenridge CB; Beck M; Jiao Y; Butt MT; Wolf JC; Zadory D; Minnema DJ; Sturgess NC; Travis KZ; Cook AR; Smith LL; Botham PA PLoS One; 2016; 11(10):e0164094. PubMed ID: 27788145 [TBL] [Abstract][Full Text] [Related]
11. MicroRNA-190 alleviates neuronal damage and inhibits neuroinflammation via Nlrp3 in MPTP-induced Parkinson's disease mouse model. Sun Q; Wang S; Chen J; Cai H; Huang W; Zhang Y; Wang L; Xing Y J Cell Physiol; 2019 Dec; 234(12):23379-23387. PubMed ID: 31232472 [TBL] [Abstract][Full Text] [Related]
12. Wnt/β-catenin signaling plays an essential role in α7 nicotinic receptor-mediated neuroprotection of dopaminergic neurons in a mouse Parkinson's disease model. Liu Y; Hao S; Yang B; Fan Y; Qin X; Chen Y; Hu J Biochem Pharmacol; 2017 Sep; 140():115-123. PubMed ID: 28551099 [TBL] [Abstract][Full Text] [Related]
13. Vitamin D Treatment Attenuates Neuroinflammation and Dopaminergic Neurodegeneration in an Animal Model of Parkinson's Disease, Shifting M1 to M2 Microglia Responses. Calvello R; Cianciulli A; Nicolardi G; De Nuccio F; Giannotti L; Salvatore R; Porro C; Trotta T; Panaro MA; Lofrumento DD J Neuroimmune Pharmacol; 2017 Jun; 12(2):327-339. PubMed ID: 27987058 [TBL] [Abstract][Full Text] [Related]
14. Hyperbaric Oxygen Therapy Improves Parkinson's Disease by Promoting Mitochondrial Biogenesis via the SIRT-1/PGC-1α Pathway. Hsu HT; Yang YL; Chang WH; Fang WY; Huang SH; Chou SH; Lo YC Biomolecules; 2022 Apr; 12(5):. PubMed ID: 35625589 [TBL] [Abstract][Full Text] [Related]
15. Novel para-phenyl substituted diindolylmethanes protect against MPTP neurotoxicity and suppress glial activation in a mouse model of Parkinson's disease. De Miranda BR; Popichak KA; Hammond SL; Miller JA; Safe S; Tjalkens RB Toxicol Sci; 2015 Feb; 143(2):360-73. PubMed ID: 25406165 [TBL] [Abstract][Full Text] [Related]
16. FLZ protects dopaminergic neuron through activating protein kinase B/mammalian target of rapamycin pathway and inhibiting RTP801 expression in Parkinson's disease models. Bao XQ; Kong XC; Qian C; Zhang D Neuroscience; 2012 Jan; 202():396-404. PubMed ID: 22138155 [TBL] [Abstract][Full Text] [Related]
17. BMAL1 regulation of microglia-mediated neuroinflammation in MPTP-induced Parkinson's disease mouse model. Liu WW; Wei SZ; Huang GD; Liu LB; Gu C; Shen Y; Wang XH; Xia ST; Xie AM; Hu LF; Wang F; Liu CF FASEB J; 2020 May; 34(5):6570-6581. PubMed ID: 32246801 [TBL] [Abstract][Full Text] [Related]
18. Combined 1-Deoxynojirimycin and Ibuprofen Treatment Decreases Microglial Activation, Phagocytosis and Dopaminergic Degeneration in MPTP-Treated Mice. Costa T; Fernandez-Villalba E; Izura V; Lucas-Ochoa AM; Menezes-Filho NJ; Santana RC; de Oliveira MD; Araújo FM; Estrada C; Silva V; Costa SL; Herrero MT J Neuroimmune Pharmacol; 2021 Jun; 16(2):390-402. PubMed ID: 32564332 [TBL] [Abstract][Full Text] [Related]